+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Molecular Diagnostics Market Size, Share & Trends Analysis Report by Technology (PCR, INAAT, Sequencing, Mass Spectrometry, TMA), by Product, by Test Location, by Application, by Region, and Segment Forecasts, 2021-2028

  • ID: 4764587
  • Report
  • April 2021
  • Region: Global
  • 270 Pages
  • Grand View Research

FEATURED COMPANIES

  • Abbott
  • bioMérieux SA
  • Danaher Corporation
  • F. Hoffmann-La Roche Ltd
  • GRIFOLs S.A.
  • Hologic, Inc. (Gen Probe)
The global molecular diagnostics market size is expected to reach USD 49.3 billion by 2028. The market is expected to expand at a CAGR of 3.9% from 2021 to 2028. This growth is owing to factors such as an increasing geriatric population, the outbreak of COVID-19, and the growing demand for point-of-care facilities.



Molecular diagnostics play an important role in infectious disease testing as they can yield effective and fast results. Hence, the increasing prevalence of hospital-acquired infections and infectious diseases is projected to drive the market over the forecast period. Increasing incidence of cardiovascular, neurological, and genetic disorders is further anticipated to accelerate market growth.

The miniaturization of three basic molecular assays - nanobiotechnology, biochips, and microfluidics - is expected to increase the accuracy and specificity of diagnostic outcomes, and hence, increase the demand for molecular diagnostic products. These improvements are expected to enhance the availability of PoC molecular diagnostic tests to yield quick and effective test results.

Companies expanding their regional presence owing to approval of COVID-19 IVD tests are expected to boost the market growth. For instance, Vela Diagnostics received the CE-IVD mark for ViroKey SARS-CoV-2 RT-PCR Test. It is a probe-based RT-PCR test used on Applied Biosystems 7500 Fast Dx instrument to detect SARS-CoV-2. The CE-IVD mark has enabled Vela diagnostics to expand its COVID-19 test in Europe.

Key players are enhancing their range of testing options for real-time PCR instruments by increasing R&D activities for the development of kits that target emerging diseases, or by entering into agreements with other kit manufacturing companies. These include the introduction of Cobas HPV test assay in Cobas 4800 by Roche Diagnostics. The introduction of tuberculosis testing Xpert assay on GeneXpert platform by Cepheid is an example of such advancement. Such advances are anticipated to drive the market.

Molecular Diagnostics Market Report Highlights

  • The reagents segment dominated the market majorly driven by the high usage rate
  • The PCR technology segment accounted for the highest revenue share in 2020, attributable to its wide usage in the diagnosis of COVID-19 and other infectious diseases
  • The self-testing or OTC segment is anticipated to be the fastest-growing segment over the forecast period as it facilitates early diagnosis and constant patient monitoring
  • North America accounted for the highest revenue share in 2020, driven by a high disease prevalence, rising consumer awareness, proactive government measures, technological advancements, and improvements in healthcare infrastructure
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Abbott
  • bioMérieux SA
  • Danaher Corporation
  • F. Hoffmann-La Roche Ltd
  • GRIFOLs S.A.
  • Hologic, Inc. (Gen Probe)
Chapter 1 Methodology and Scope
1.1 Market Segmentation
1.1.1 Estimates and Forecast Timeline
1.2 Research Methodology
1.3 Information Procurement
1.3.1 Purchased Database
1.3.2 Secondary Sources
1.3.3 Primary Research
1.3.4 Details of Primary Research
1.4 Information or Data Analysis
1.4.1 Data Analysis Models
1.5 Market Formulation & Validation
1.6 Model Details
1.6.1 Commodity Flow Analysis
1.6.1.1 Approach 1: Commodity flow approach
1.6.1.2 Approach 2: Country wise market estimation using bottom up approach
1.7 Global Market: CAGR Calculation
1.8 Research Assumptions
1.9 List of Secondary Sources
1.10 List of Primary Sources
1.11 Objectives
1.11.1 Objective 1:
1.11.2 Objective 2:
1.12 List of Abbreviations

Chapter 2 Executive Summary
2.1 Market Summary

Chapter 3 Molecular Diagnostics Market Variables, Trends & Scope
3.1 Molecular Diagnostics Market Lineage Outlook
3.1.1 Parent market outlook
3.2 Penetration & Growth Prospect Mapping
3.3 Regulatory and Reimbursement Framework
3.4 CLIA Waived Tests and Instruments
3.5 Market Dynamics
3.5.1 Market Driver Analysis
3.5.1.1 Increase in geriatric population
3.5.1.2 Introduction of technologically advanced products
3.5.1.3 Increase in demand for point-of-care facilities
3.5.1.4 Growing prevalence of target diseases
3.5.1.5 Increasing external funding for R&D
3.5.1.6 Outbreak of COVID-19
3.5.2 Market Restraint Analysis
3.5.2.1 Presence of ambiguous regulatory framework
3.5.2.2 High prices of molecular diagnostics tests
3.6 Molecular Diagnostics Market Analysis Tools
3.6.1 Porter’s Five Forces Analysis
3.6.2 SWOT Analysis; By factor (Political & Legal, Economic and Technological)
3.6.3 Major Deals & Strategic Alliances Analysis
3.6.3.1 New product launch
3.6.3.2 Mergers and acquisitions
3.6.3.3 Expansion
3.6.3.4 Partnerships
3.6.3.5 Marketing & promotions
3.6.3.6 Market entry strategies

Chapter 4 Molecular Diagnostics Market - Competitive Analysis
4.1 Recent Developments & Impact Analysis, by Key Market Participants
4.1.1 Company/Competition Categorization (Key innovators, Market leaders, Expansion)
4.1.2 Innovators
4.1.3 Key Differentiators
4.2 Vendor Landscape
4.2.1 List of key distributors
4.2.2 Key Company Market Share Analysis, 2020
4.2.2.1 Market share analysis, by Application, 2020
4.2.2.1.1 Market share analysis, Molecular diagnostics, Oncology, 2020
4.2.2.1.2 Market share analysis, Molecular diagnostics, Pharmacogenomics, 2020
4.2.2.1.3 Market share analysis, Molecular diagnostics, Infectious Diseases, 2020
4.2.2.1.4 Market share analysis, Molecular diagnostics, Genetic Testing, 2020
4.2.2.1.5 Market share analysis, Molecular diagnostics, Others (Neurological disease, Cardiovascular Diseases, Microbiology, Others) 2020
4.2.2.2 Market share analysis, by Technology, 2020
4.2.2.2.1 Market share analysis, Molecular diagnostics, Polymerase Chain Reaction, 2020
4.2.2.2.2 Market share analysis, Molecular diagnostics, In Situ Hybridization, 2020
4.2.2.2.3 Market share analysis, Molecular diagnostics, INAAT, 2020
4.2.2.2.4 Market share analysis, Molecular diagnostics, Chips & Microarrays, 2020
4.2.2.2.5 Market share analysis, Molecular diagnostics, Mass Spectrometry, 2020
4.2.2.2.6 Market share analysis, Molecular diagnostics, Sequencing, 2020
4.2.2.2.7 Market share analysis, Molecular diagnostics, Transcription Mediated Amplification, 2020
4.2.2.3 Market share analysis, by Application, 2020
4.2.2.3.1 Market share analysis, Molecular diagnostics, Oncology, 2020
4.2.2.3.2 Market share analysis, Molecular diagnostics, Pharmacogenomics, 2020
4.2.2.3.3 Market share analysis, Molecular diagnostics, Infectious Diseases, 2020
4.2.2.3.4 Market share analysis, Molecular diagnostics, Genetic Testing, 2020
4.2.2.3.5 Market share analysis, Molecular diagnostics, Others (Neurological disease, Cardiovascular Diseases, Microbiology, Others) 2020
4.2.2.4 Market share analysis, by Technology, 2020
4.2.2.4.1 Market share analysis, Molecular diagnostics, Polymerase Chain Reaction, 2020
4.2.2.4.2 Market share analysis, Molecular diagnostics, In Situ Hybridization, 2020
4.2.2.4.3 Market share analysis, Molecular diagnostics, INAAT, 2020
4.2.2.4.4 Market share analysis, Molecular diagnostics, Chips & Microarrays, 2020
4.2.2.4.5 Market share analysis, Molecular diagnostics, Mass Spectrometry, 2020
4.2.2.4.6 Market share analysis, Molecular diagnostics, Sequencing, 2020
4.2.2.4.7 Market share analysis, Molecular diagnostics, Transcription Mediated Amplification, 2020
4.2.2.5 Market share analysis, by Application, 2020
4.2.2.5.1 Market share analysis, Molecular diagnostics, Oncology, 2020
4.2.2.5.2 Market share analysis, Molecular diagnostics, Pharmacogenomics, 2020
4.2.2.5.3 Market share analysis, Molecular diagnostics, Infectious Diseases, 2020
4.2.2.5.4 Market share analysis, Molecular diagnostics, Genetic Testing, 2020
4.2.2.5.5 Market share analysis, Molecular diagnostics, Others (Neurological disease, Cardiovascular Diseases, Microbiology, Others) 2020
4.2.2.6 Market share analysis, by Technology, 2020
4.2.2.6.1 Market share analysis, Molecular diagnostics, Polymerase Chain Reaction, 2020
4.2.2.6.2 Market share analysis, Molecular diagnostics, In Situ Hybridization, 2020
4.2.2.6.3 Market share analysis, Molecular diagnostics, INAAT, 2020
4.2.2.6.4 Market share analysis, Molecular diagnostics, Chips & Microarrays, 2020
4.2.2.6.5 Market share analysis, Molecular diagnostics, Mass Spectrometry, 2020
4.2.2.6.6 Market share analysis, Molecular diagnostics, Sequencing, 2020
4.2.2.6.7 Market share analysis, Molecular diagnostics, Transcription Mediated Amplification, 2020
4.2.2.7 Market share analysis, by Application, 2020
4.2.2.7.1 Market share analysis, Molecular diagnostics, Oncology, 2020
4.2.2.7.2 Market share analysis, Molecular diagnostics, Pharmacogenomics, 2020
4.2.2.7.3 Market share analysis, Molecular diagnostics, Infectious Diseases, 2020
4.2.2.7.4 Market share analysis, Molecular diagnostics, Genetic Testing, 2020
4.2.2.7.5 Market share analysis, Molecular diagnostics, Others (Neurological disease, Cardiovascular Diseases, Microbiology, Others) 2020
4.2.2.8 Market share analysis, by Technology, 2020
4.2.2.8.1 Market share analysis, Molecular diagnostics, Polymerase Chain Reaction, 2020
4.2.2.8.2 Market share analysis, Molecular diagnostics, In Situ Hybridization, 2020
4.2.2.8.3 Market share analysis, Molecular diagnostics, INAAT, 2020
4.2.2.8.4 Market share analysis, Molecular diagnostics, Chips & Microarrays, 2020
4.2.2.8.5 Market share analysis, Molecular diagnostics, Mass Spectrometry, 2020
4.2.2.8.6 Market share analysis, Molecular diagnostics, Sequencing, 2020
4.2.2.8.7 Market share analysis, Molecular diagnostics, Transcription Mediated Amplification, 2020
4.2.2.9 Market share analysis, by Application, 2020
4.2.2.9.1 Market share analysis, Molecular diagnostics, Oncology, 2020
4.2.2.9.2 Market share analysis, Molecular diagnostics, Pharmacogenomics, 2020
4.2.2.9.3 Market share analysis, Molecular diagnostics, Infectious Diseases, 2020
4.2.2.9.4 Market share analysis, Molecular diagnostics, Genetic Testing, 2020
4.2.2.9.5 Market share analysis, Molecular diagnostics, Others (Neurological disease, Cardiovascular Diseases, Microbiology, Others) 2020
4.2.2.10 Market share analysis, by Technology, 2020
4.2.2.10.1 Market share analysis, Molecular diagnostics, Polymerase Chain Reaction, 2020
4.2.2.10.2 Market share analysis, Molecular diagnostics, In Situ Hybridization, 2020
4.2.2.10.3 Market share analysis, Molecular diagnostics, INAAT, 2020
4.2.2.10.4 Market share analysis, Molecular diagnostics, Chips & Microarrays, 2020
4.2.2.10.5 Market share analysis, Molecular diagnostics, Mass Spectrometry, 2020
4.2.2.10.6 Market share analysis, Molecular diagnostics, Sequencing, 2020
4.2.2.10.7 Market share analysis, Molecular diagnostics, Transcription Mediated Amplification, 2020
4.2.2.11 Market share analysis, by Application, 2020
4.2.2.11.1 Market share analysis, Molecular diagnostics, Oncology, 2020
4.2.2.11.2 Market share analysis, Molecular diagnostics, Pharmacogenomics, 2020
4.2.2.11.3 Market share analysis, Molecular diagnostics, Infectious Diseases, 2020
4.2.2.11.4 Market share analysis, Molecular diagnostics, Genetic Testing, 2020
4.2.2.11.5 Market share analysis, Molecular diagnostics, Others (Neurological disease, Cardiovascular Diseases, Microbiology, Others) 2020
4.2.2.12 Market share analysis, by Technology, 2020
4.2.2.12.1 Market share analysis, Molecular diagnostics, Polymerase Chain Reaction, 2020
4.2.2.12.2 Market share analysis, Molecular diagnostics, In Situ Hybridization, 2020
4.2.2.12.3 Market share analysis, Molecular diagnostics, INAAT, 2020
4.2.2.12.4 Market share analysis, Molecular diagnostics, Chips & Microarrays, 2020
4.2.2.12.5 Market share analysis, Molecular diagnostics, Mass Spectrometry, 2020
4.2.2.12.6 Market share analysis, Molecular diagnostics, Sequencing, 2020
4.2.2.12.7 Market share analysis, Molecular diagnostics, Transcription Mediated Amplification, 2020
4.3 Public Companies
4.3.1 Company Market Position Analysis (2020)
4.3.2 Competitive Dashboard Analysis
4.4 Private Companies
4.4.1 List of Key Emerging Companies /Technology Disruptors/Innovators
4.4.2 Regional Network Map
4.4.3 Competitive Dashboard Analysis

Chapter 5 Products Business Analysis
5.1 Molecular Diagnostics Market: Products Movement Analysis
5.1.1 Instruments
5.1.1.1 Instruments market estimates and forecast, 2017 - 2028 (USD Million)
5.1.2 Reagents
5.1.2.1 Reagents market estimates and forecast, 2017 - 2028 (USD Million)
5.1.3 Others
5.1.3.1 Others market estimates and forecast, 2017 - 2028 (USD Million)

Chapter 6 Test Location Business Analysis
6.1 Molecular Diagnostics Market: Test Location Movement Analysis
6.1.1 Point-of-Care
6.1.1.1 Point-of-care market estimates and forecast, 2017 - 2028 (USD Million)
6.1.2 Self-testing or Over the Counter
6.1.2.1 Self-testing or over the counter market estimates and forecast, 2017 - 2028 (USD Million)
6.1.3 Central Laboratories
6.1.3.1 Central laboratories market estimates and forecast, 2017 - 2028 (USD Million)

List of Tables
Table 1 Country share estimation
Table 2 North America molecular diagnostics market estimates and forecasts, by product, 2017 - 2028 (USD Million)
Table 3 North America molecular diagnostics market estimates and forecasts, by test location, 2017 - 2028 (USD Million)
Table 4 North America molecular diagnostics market estimates and forecasts, by technology, 2017 - 2028 (USD Million)
Table 5 North America PCR market estimates and forecasts, by type, 2017 - 2028 (USD Million)
Table 6 North America PCR market estimates and forecasts, by product, 2017 - 2028 (USD Million)
Table 7 North America ISH market estimates and forecasts, by product, 2017 - 2028 (USD Million)
Table 8 North America INAAT market estimates and forecasts, by product, 2017 - 2028 (USD Million)
Table 9 North America chips and microarrays market estimates and forecasts, by product, 2017 - 2028 (USD Million)
Table 10 North America mass spectrometry market estimates and forecasts, by product, 2017 - 2028 (USD Million)
Table 11 North America sequencing market estimates and forecasts, by product, 2017 - 2028 (USD Million)
Table 12 North America TMA market estimates and forecasts, by product, 2017 - 2028 (USD Million)
Table 13 North America others technology market estimates and forecasts, by product, 2017 - 2028 (USD Million)
Table 14 North America molecular diagnostics market estimates and forecasts, by application, 2017 - 2028 (USD Million)
Table 15 North America molecular diagnostics market estimates and forecasts, by oncology, 2017 - 2028 (USD Million)
Table 16 North America molecular diagnostics market estimates and forecasts, by infectious diseases, 2017 - 2028 (USD Million)
Table 17 North America molecular diagnostics market estimates and forecasts, by genetic testing, 2017 - 2028 (USD Million)
Table 18 U.S. molecular diagnostics market estimates and forecasts, by product, 2017 - 2028 (USD Million)
Table 19 U.S. molecular diagnostics market estimates and forecasts, by test location, 2017 - 2028 (USD Million)
Table 20 U.S. molecular diagnostics market estimates and forecasts, by technology, 2017 - 2028 (USD Million)
Table 21 U.S. PCR market estimates and forecasts, by type, 2017 - 2028 (USD Million)
Table 22 U.S. PCR market estimates and forecasts, by product, 2017 - 2028 (USD Million)
Table 23 U.S. ISH market estimates and forecasts, by product, 2017 - 2028 (USD Million)
Table 24 U.S. INAAT market estimates and forecasts, by product, 2017 - 2028 (USD Million)
Table 25 U.S. chips and microarrays market estimates and forecasts, by product, 2017 - 2028 (USD Million)
Table 26 U.S. mass spectrometry market estimates and forecasts, by product, 2017 - 2028 (USD Million)
Table 27 U.S. sequencing market estimates and forecasts, by product, 2017 - 2028 (USD Million)
Table 28 U.S. TMA market estimates and forecasts, by product, 2017 - 2028 (USD Million)
Table 29 U.S. others technology market estimates and forecasts, by product, 2017 - 2028 (USD Million)
Table 30 U.S. molecular diagnostics market estimates and forecasts, by application, 2017 - 2028 (USD Million)
Table 31 U.S. molecular diagnostics market estimates and forecasts, by oncology, 2017 - 2028 (USD Million)
Table 32 U.S. molecular diagnostics market estimates and forecasts, by infectious diseases, 2017 - 2028 (USD Million)
Table 33 U.S. molecular diagnostics market estimates and forecasts, by genetic testing, 2017 - 2028 (USD Million)
Table 34 Canada molecular diagnostics market estimates and forecasts, by product, 2017 - 2028 (USD Million)
Table 35 Canada molecular diagnostics market estimates and forecasts, by test location, 2017 - 2028 (USD Million)
Table 36 Canada molecular diagnostics market estimates and forecasts, by technology, 2017 - 2028 (USD Million)
Table 37 Canada PCR market estimates and forecasts, by type, 2017 - 2028 (USD Million)
Table 38 Canada PCR market estimates and forecasts, by product, 2017 - 2028 (USD Million)
Table 39 Canada ISH market estimates and forecasts, by product, 2017 - 2028 (USD Million)
Table 40 Canada INAAT market estimates and forecasts, by product, 2017 - 2028 (USD Million)
Table 41 Canada chips and microarrays market estimates and forecasts, by product, 2017 - 2028 (USD Million)
Table 42 Canada mass spectrometry market estimates and forecasts, by product, 2017 - 2028 (USD Million)
Table 43 Canada sequencing market estimates and forecasts, by product, 2017 - 2028 (USD Million)
Table 44 Canada TMA market estimates and forecasts, by product, 2017 - 2028 (USD Million)
Table 45 Canada others technology market estimates and forecasts, by product, 2017 - 2028 (USD Million)
Table 46 Canada molecular diagnostics market estimates and forecasts, by application, 2017 - 2028 (USD Million)
Table 47 Canada molecular diagnostics market estimates and forecasts, by oncology, 2017 - 2028 (USD Million)
Table 48 Canada molecular diagnostics market estimates and forecasts, by infectious diseases, 2017 - 2028 (USD Million)
Table 49 Canada molecular diagnostics market estimates and forecasts, by genetic testing, 2017 - 2028 (USD Million)
Table 50 Europe molecular diagnostics market estimates and forecasts, by product, 2017 - 2028 (USD Million)
Table 51 Europe molecular diagnostics market estimates and forecasts, by test location, 2017 - 2028 (USD Million)
Table 52 Europe molecular diagnostics market estimates and forecasts, by technology, 2017 - 2028 (USD Million)
Table 53 Europe PCR market estimates and forecasts, by type, 2017 - 2028 (USD Million)
Table 54 Europe PCR market estimates and forecasts, by product, 2017 - 2028 (USD Million)
Table 55 Europe ISH market estimates and forecasts, by product, 2017 - 2028 (USD Million)
Table 56 Europe INAAT market estimates and forecasts, by product, 2017 - 2028 (USD Million)
Table 57 Europe chips and microarrays market estimates and forecasts, by product, 2017 - 2028 (USD Million)
Table 58 Europe mass spectrometry market estimates and forecasts, by product, 2017 - 2028 (USD Million)
Table 59 Europe sequencing market estimates and forecasts, by product, 2017 - 2028 (USD Million)
Table 60 Europe TMA market estimates and forecasts, by product, 2017 - 2028 (USD Million)
Table 61 Europe others technology market estimates and forecasts, by product, 2017 - 2028 (USD Million)
Table 62 Europe molecular diagnostics market estimates and forecasts, by application, 2017 - 2028 (USD Million)
Table 63 Europe molecular diagnostics market estimates and forecasts, by oncology, 2017 - 2028 (USD Million)
Table 64 Europe molecular diagnostics market estimates and forecasts, by infectious diseases, 2017 - 2028 (USD Million)
Table 65 Europe molecular diagnostics market estimates and forecasts, by genetic testing, 2017 - 2028 (USD Million)
Table 66 U.K. molecular diagnostics market estimates and forecasts, by product, 2017 - 2028 (USD Million)
Table 67 U.K. molecular diagnostics market estimates and forecasts, by test location, 2017 - 2028 (USD Million)
Table 68 U.K. molecular diagnostics market estimates and forecasts, by technology, 2017 - 2028 (USD Million)
Table 69 U.K. PCR market estimates and forecasts, by type, 2017 - 2028 (USD Million)
Table 70 U.K. PCR market estimates and forecasts, by product, 2017 - 2028 (USD Million)
Table 71 U.K. ISH market estimates and forecasts, by product, 2017 - 2028 (USD Million)
Table 72 U.K. INAAT market estimates and forecasts, by product, 2017 - 2028 (USD Million)
Table 73 U.K. chips and microarrays market estimates and forecasts, by product, 2017 - 2028 (USD Million)
Table 74 U.K. mass spectrometry market estimates and forecasts, by product, 2017 - 2028 (USD Million)
Table 75 U.K. sequencing market estimates and forecasts, by product, 2017 - 2028 (USD Million)
Table 76 U.K. TMA market estimates and forecasts, by product, 2017 - 2028 (USD Million)
Table 77 U.K. others technology market estimates and forecasts, by product, 2017 - 2028 (USD Million)
Table 78 U.K. molecular diagnostics market estimates and forecasts, by application, 2017 - 2028 (USD Million)
Table 79 U.K. molecular diagnostics market estimates and forecasts, by oncology, 2017 - 2028 (USD Million)
Table 80 U.K. molecular diagnostics market estimates and forecasts, by infectious diseases, 2017 - 2028 (USD Million)
Table 81 U.K. molecular diagnostics market estimates and forecasts, by genetic testing, 2017 - 2028 (USD Million)
Table 82 Germany molecular diagnostics market estimates and forecasts, by product, 2017 - 2028 (USD Million)
Table 83 Germany molecular diagnostics market estimates and forecasts, by test location, 2017 - 2028 (USD Million)
Table 84 Germany molecular diagnostics market estimates and forecasts, by technology, 2017 - 2028 (USD Million)
Table 85 Germany PCR market estimates and forecasts, by type, 2017 - 2028 (USD Million)
Table 86 Germany PCR market estimates and forecasts, by product, 2017 - 2028 (USD Million)
Table 87 Germany ISH market estimates and forecasts, by product, 2017 - 2028 (USD Million)
Table 88 Germany INAAT market estimates and forecasts, by product, 2017 - 2028 (USD Million)
Table 89 Germany chips and microarrays market estimates and forecasts, by product, 2017 - 2028 (USD Million)
Table 90 Germany mass spectrometry market estimates and forecasts, by product, 2017 - 2028 (USD Million)
Table 91 Germany sequencing market estimates and forecasts, by product, 2017 - 2028 (USD Million)
Table 92 Germany TMA market estimates and forecasts, by product, 2017 - 2028 (USD Million)
Table 93 Germany others technology market estimates and forecasts, by product, 2017 - 2028 (USD Million)
Table 94 Germany molecular diagnostics market estimates and forecasts, by application, 2017 - 2028 (USD Million)
Table 95 Germany molecular diagnostics market estimates and forecasts, by oncology, 2017 - 2028 (USD Million)
Table 96 Germany molecular diagnostics market estimates and forecasts, by infectious diseases, 2017 - 2028 (USD Million)
Table 97 Germany molecular diagnostics market estimates and forecasts, by genetic testing, 2017 - 2028 (USD Million)
Table 98 France molecular diagnostics market estimates and forecasts, by product, 2017 - 2028 (USD Million)
Table 99 France molecular diagnostics market estimates and forecasts, by test location, 2017 - 2028 (USD Million)
Table 100 France molecular diagnostics market estimates and forecasts, by technology, 2017 - 2028 (USD Million)
Table 101 France PCR market estimates and forecasts, by type, 2017 - 2028 (USD Million)
Table 102 France PCR market estimates and forecasts, by product, 2017 - 2028 (USD Million)
Table 103 France ISH market estimates and forecasts, by product, 2017 - 2028 (USD Million)
Table 104 France INAAT market estimates and forecasts, by product, 2017 - 2028 (USD Million)
Table 105 France chips and microarrays market estimates and forecasts, by product, 2017 - 2028 (USD Million)
Table 106 France mass spectrometry market estimates and forecasts, by product, 2017 - 2028 (USD Million)
Table 107 France sequencing market estimates and forecasts, by product, 2017 - 2028 (USD Million)
Table 108 France TMA market estimates and forecasts, by product, 2017 - 2028 (USD Million)
Table 109 France others technology market estimates and forecasts, by product, 2017 - 2028 (USD Million)
Table 110 France molecular diagnostics market estimates and forecasts, by application, 2017 - 2028 (USD Million)
Table 111 France molecular diagnostics market estimates and forecasts, by oncology, 2017 - 2028 (USD Million)
Table 112 France molecular diagnostics market estimates and forecasts, by infectious diseases, 2017 - 2028 (USD Million)
Table 113 France molecular diagnostics market estimates and forecasts, by genetic testing, 2017 - 2028 (USD Million)
Table 114 Spain molecular diagnostics market estimates and forecasts, by product, 2017 - 2028 (USD Million)
Table 115 Spain molecular diagnostics market estimates and forecasts, by test location, 2017 - 2028 (USD Million)
Table 116 Spain molecular diagnostics market estimates and forecasts, by technology, 2017 - 2028 (USD Million)
Table 117 Spain PCR market estimates and forecasts, by type, 2017 - 2028 (USD Million)
Table 118 Spain PCR market estimates and forecasts, by product, 2017 - 2028 (USD Million)
Table 119 Spain ISH market estimates and forecasts, by product, 2017 - 2028 (USD Million)
Table 120 Spain INAAT market estimates and forecasts, by product, 2017 - 2028 (USD Million)
Table 121 Spain chips and microarrays market estimates and forecasts, by product, 2017 - 2028 (USD Million)
Table 122 Spain mass spectrometry market estimates and forecasts, by product, 2017 - 2028 (USD Million)
Table 123 Spain sequencing market estimates and forecasts, by product, 2017 - 2028 (USD Million)
Table 124 Spain TMA market estimates and forecasts, by product, 2017 - 2028 (USD Million)
Table 125 Spain others technology market estimates and forecasts, by product, 2017 - 2028 (USD Million)
Table 126 Spain molecular diagnostics market estimates and forecasts, by application, 2017 - 2028 (USD Million)
Table 127 Spain molecular diagnostics market estimates and forecasts, by oncology, 2017 - 2028 (USD Million)
Table 128 Spain molecular diagnostics market estimates and forecasts, by infectious diseases, 2017 - 2028 (USD Million)
Table 129 Spain molecular diagnostics market estimates and forecasts, by genetic testing, 2017 - 2028 (USD Million)
Table 130 Italy molecular diagnostics market estimates and forecasts, by product, 2017 - 2028 (USD Million)
Table 131 Italy molecular diagnostics market estimates and forecasts, by test location, 2017 - 2028 (USD Million)
Table 132 Italy molecular diagnostics market estimates and forecasts, by technology, 2017 - 2028 (USD Million)
Table 133 Italy PCR market estimates and forecasts, by type, 2017 - 2028 (USD Million)
Table 134 Italy PCR market estimates and forecasts, by product, 2017 - 2028 (USD Million)
Table 135 Italy ISH market estimates and forecasts, by product, 2017 - 2028 (USD Million)
Table 136 Italy INAAT market estimates and forecasts, by product, 2017 - 2028 (USD Million)
Table 137 Italy chips and microarrays market estimates and forecasts, by product, 2017 - 2028 (USD Million)
Table 138 Italy mass spectrometry market estimates and forecasts, by product, 2017 - 2028 (USD Million)
Table 139 Italy sequencing market estimates and forecasts, by product, 2017 - 2028 (USD Million)
Table 140 Italy TMA market estimates and forecasts, by product, 2017 - 2028 (USD Million)
Table 141 Italy others technology market estimates and forecasts, by product, 2017 - 2028 (USD Million)
Table 142 Italy molecular diagnostics market estimates and forecasts, by application, 2017 - 2028 (USD Million)
Table 143 Italy molecular diagnostics market estimates and forecasts, by oncology, 2017 - 2028 (USD Million)
Table 144 Italy molecular diagnostics market estimates and forecasts, by infectious diseases, 2017 - 2028 (USD Million)
Table 145 Italy molecular diagnostics market estimates and forecasts, by genetic testing, 2017 - 2028 (USD Million)
Table 146 Belgium molecular diagnostics market estimates and forecasts, by product, 2017 - 2028 (USD Million)
Table 147 Belgium molecular diagnostics market estimates and forecasts, by test location, 2017 - 2028 (USD Million)
Table 148 Belgium molecular diagnostics market estimates and forecasts, by technology, 2017 - 2028 (USD Million)
Table 149 Belgium PCR market estimates and forecasts, by type, 2017 - 2028 (USD Million)
Table 150 Belgium PCR market estimates and forecasts, by product, 2017 - 2028 (USD Million)
Table 151 Belgium ISH market estimates and forecasts, by product, 2017 - 2028 (USD Million)
Table 152 Belgium INAAT market estimates and forecasts, by product, 2017 - 2028 (USD Million)
Table 153 Belgium chips and microarrays market estimates and forecasts, by product, 2017 - 2028 (USD Million)
Table 154 Belgium mass spectrometry market estimates and forecasts, by product, 2017 - 2028 (USD Million)
Table 155 Belgium sequencing market estimates and forecasts, by product, 2017 - 2028 (USD Million)
Table 156 Belgium TMA market estimates and forecasts, by product, 2017 - 2028 (USD Million)
Table 157 Belgium others technology market estimates and forecasts, by product, 2017 - 2028 (USD Million)
Table 158 Belgium molecular diagnostics market estimates and forecasts, by application, 2017 - 2028 (USD Million)
Table 159 Belgium molecular diagnostics market estimates and forecasts, by oncology, 2017 - 2028 (USD Million)
Table 160 Belgium molecular diagnostics market estimates and forecasts, by infectious diseases, 2017 - 2028 (USD Million)
Table 161 Belgium molecular diagnostics market estimates and forecasts, by genetic testing, 2017 - 2028 (USD Million)
Table 162 Switzerland molecular diagnostics market estimates and forecasts, by product, 2017 - 2028 (USD Million)
Table 163 Switzerland molecular diagnostics market estimates and forecasts, by test location, 2017 - 2028 (USD Million)
Table 164 Switzerland molecular diagnostics market estimates and forecasts, by technology, 2017 - 2028 (USD Million)
Table 165 Switzerland PCR market estimates and forecasts, by type, 2017 - 2028 (USD Million)
Table 166 Switzerland PCR market estimates and forecasts, by product, 2017 - 2028 (USD Million)
Table 167 Switzerland ISH market estimates and forecasts, by product, 2017 - 2028 (USD Million)
Table 168 Switzerland INAAT market estimates and forecasts, by product, 2017 - 2028 (USD Million)
Table 169 Switzerland chips and microarrays market estimates and forecasts, by product, 2017 - 2028 (USD Million)
Table 170 Switzerland mass spectrometry market estimates and forecasts, by product, 2017 - 2028 (USD Million)
Table 171 Switzerland sequencing market estimates and forecasts, by product, 2017 - 2028 (USD Million)
Table 172 Switzerland TMA market estimates and forecasts, by product, 2017 - 2028 (USD Million)
Table 173 Switzerland others technology market estimates and forecasts, by product, 2017 - 2028 (USD Million)
Table 174 Switzerland molecular diagnostics market estimates and forecasts, by application, 2017 - 2028 (USD Million)
Table 175 Switzerland molecular diagnostics market estimates and forecasts, by oncology, 2017 - 2028 (USD Million)
Table 176 Switzerland molecular diagnostics market estimates and forecasts, by infectious diseases, 2017 - 2028 (USD Million)
Table 177 Switzerland molecular diagnostics market estimates and forecasts, by genetic testing, 2017 - 2028 (USD Million)
Table 178 Netherlands molecular diagnostics market estimates and forecasts, by product, 2017 - 2028 (USD Million)
Table 179 Netherlands molecular diagnostics market estimates and forecasts, by test location, 2017 - 2028 (USD Million)
Table 180 Netherlands molecular diagnostics market estimates and forecasts, by technology, 2017 - 2028 (USD Million)
Table 181 Netherlands PCR market estimates and forecasts, by type, 2017 - 2028 (USD Million)
Table 182 Netherlands PCR market estimates and forecasts, by product, 2017 - 2028 (USD Million)
Table 183 Netherlands ISH market estimates and forecasts, by product, 2017 - 2028 (USD Million)
Table 184 Netherlands INAAT market estimates and forecasts, by product, 2017 - 2028 (USD Million)
Table 185 Netherlands chips and microarrays market estimates and forecasts, by product, 2017 - 2028 (USD Million)
Table 186 Netherlands mass spectrometry market estimates and forecasts, by product, 2017 - 2028 (USD Million)
Table 187 Netherlands sequencing market estimates and forecasts, by product, 2017 - 2028 (USD Million)
Table 188 Netherlands TMA market estimates and forecasts, by product, 2017 - 2028 (USD Million)
Table 189 Netherlands others technology market estimates and forecasts, by product, 2017 - 2028 (USD Million)
Table 190 Netherlands molecular diagnostics market estimates and forecasts, by application, 2017 - 2028 (USD Million)
Table 191 Netherlands molecular diagnostics market estimates and forecasts, by oncology, 2017 - 2028 (USD Million)
Table 192 Netherlands molecular diagnostics market estimates and forecasts, by infectious diseases, 2017 - 2028 (USD Million)
Table 193 Netherlands molecular diagnostics market estimates and forecasts, by genetic testing, 2017 - 2028 (USD Million)
Table 194 Poland molecular diagnostics market estimates and forecasts, by product, 2017 - 2028 (USD Million)
Table 195 Poland molecular diagnostics market estimates and forecasts, by test location, 2017 - 2028 (USD Million)
Table 196 Poland molecular diagnostics market estimates and forecasts, by technology, 2017 - 2028 (USD Million)
Table 197 Poland PCR market estimates and forecasts, by type, 2017 - 2028 (USD Million)
Table 198 Poland PCR market estimates and forecasts, by product, 2017 - 2028 (USD Million)
Table 199 Poland ISH market estimates and forecasts, by product, 2017 - 2028 (USD Million)
Table 200 Poland INAAT market estimates and forecasts, by product, 2017 - 2028 (USD Million)
Table 201 Poland chips and microarrays market estimates and forecasts, by product, 2017 - 2028 (USD Million)
Table 202 Poland mass spectrometry market estimates and forecasts, by product, 2017 - 2028 (USD Million)
Table 203 Poland sequencing market estimates and forecasts, by product, 2017 - 2028 (USD Million)
Table 204 Poland TMA market estimates and forecasts, by product, 2017 - 2028 (USD Million)
Table 205 Poland others technology market estimates and forecasts, by product, 2017 - 2028 (USD Million)
Table 206 Poland molecular diagnostics market estimates and forecasts, by application, 2017 - 2028 (USD Million)
Table 207 Poland molecular diagnostics market estimates and forecasts, by oncology, 2017 - 2028 (USD Million)
Table 208 Poland molecular diagnostics market estimates and forecasts, by infectious diseases, 2017 - 2028 (USD Million)
Table 209 Poland molecular diagnostics market estimates and forecasts, by genetic testing, 2017 - 2028 (USD Million)
Table 210 Austria molecular diagnostics market estimates and forecasts, by product, 2017 - 2028 (USD Million)
Table 211 Austria molecular diagnostics market estimates and forecasts, by test location, 2017 - 2028 (USD Million)
Table 212 Austria molecular diagnostics market estimates and forecasts, by technology, 2017 - 2028 (USD Million)
Table 213 Austria PCR market estimates and forecasts, by type, 2017 - 2028 (USD Million)
Table 214 Austria PCR market estimates and forecasts, by product, 2017 - 2028 (USD Million)
Table 215 Austria ISH market estimates and forecasts, by product, 2017 - 2028 (USD Million)
Table 216 Austria INAAT market estimates and forecasts, by product, 2017 - 2028 (USD Million)
Table 217 Austria chips and microarrays market estimates and forecasts, by product, 2017 - 2028 (USD Million)
Table 218 Austria mass spectrometry market estimates and forecasts, by product, 2017 - 2028 (USD Million)
Table 219 Austria sequencing market estimates and forecasts, by product, 2017 - 2028 (USD Million)
Table 220 Austria TMA market estimates and forecasts, by product, 2017 - 2028 (USD Million)
Table 221 Austria others technology market estimates and forecasts, by product, 2017 - 2028 (USD Million)
Table 222 Austria molecular diagnostics market estimates and forecasts, by application, 2017 - 2028 (USD Million)
Table 223 Austria molecular diagnostics market estimates and forecasts, by oncology, 2017 - 2028 (USD Million)
Table 224 Austria molecular diagnostics market estimates and forecasts, by infectious diseases, 2017 - 2028 (USD Million)
Table 225 Austria molecular diagnostics market estimates and forecasts, by genetic testing, 2017 - 2028 (USD Million)
Table 226 Greece molecular diagnostics market estimates and forecasts, by product, 2017 - 2028 (USD Million)
Table 227 Greece molecular diagnostics market estimates and forecasts, by test location, 2017 - 2028 (USD Million)
Table 228 Greece molecular diagnostics market estimates and forecasts, by technology, 2017 - 2028 (USD Million)
Table 229 Greece PCR market estimates and forecasts, by type, 2017 - 2028 (USD Million)
Table 230 Greece PCR market estimates and forecasts, by product, 2017 - 2028 (USD Million)
Table 231 Greece ISH market estimates and forecasts, by product, 2017 - 2028 (USD Million)
Table 232 Greece INAAT market estimates and forecasts, by product, 2017 - 2028 (USD Million)
Table 233 Greece chips and microarrays market estimates and forecasts, by product, 2017 - 2028 (USD Million)
Table 234 Greece mass spectrometry market estimates and forecasts, by product, 2017 - 2028 (USD Million)
Table 235 Greece sequencing market estimates and forecasts, by product, 2017 - 2028 (USD Million)
Table 236 Greece TMA market estimates and forecasts, by product, 2017 - 2028 (USD Million)
Table 237 Greece others technology market estimates and forecasts, by product, 2017 - 2028 (USD Million)
Table 238 Greece molecular diagnostics market estimates and forecasts, by application, 2017 - 2028 (USD Million)
Table 239 Greece molecular diagnostics market estimates and forecasts, by oncology, 2017 - 2028 (USD Million)
Table 240 Greece molecular diagnostics market estimates and forecasts, by infectious diseases, 2017 - 2028 (USD Million)
Table 241 Greece molecular diagnostics market estimates and forecasts, by genetic testing, 2017 - 2028 (USD Million)
Table 242 Sweden molecular diagnostics market estimates and forecasts, by product, 2017 - 2028 (USD Million)
Table 243 Sweden molecular diagnostics market estimates and forecasts, by test location, 2017 - 2028 (USD Million)
Table 244 Sweden molecular diagnostics market estimates and forecasts, by technology, 2017 - 2028 (USD Million)
Table 245 Sweden PCR market estimates and forecasts, by type, 2017 - 2028 (USD Million)
Table 246 Sweden PCR market estimates and forecasts, by product, 2017 - 2028 (USD Million)
Table 247 Sweden ISH market estimates and forecasts, by product, 2017 - 2028 (USD Million)
Table 248 Sweden INAAT market estimates and forecasts, by product, 2017 - 2028 (USD Million)
Table 249 Sweden chips and microarrays market estimates and forecasts, by product, 2017 - 2028 (USD Million)
Table 250 Sweden mass spectrometry market estimates and forecasts, by product, 2017 - 2028 (USD Million)

List of Figures
Fig. 1 Molecular diagnostics market segmentation
Fig. 2 Market research process
Fig. 3 Data triangulation techniques
Fig. 4 Primary research pattern
Fig. 5 Market research approaches
Fig. 6 Value-chain-based sizing & forecasting
Fig. 7 QFD modeling for market share assessment
Fig. 8 Market formulation & validation
Fig. 9 Molecular diagnostics market snapshot
Fig. 10 Parent market outlook
Fig. 11 Penetration & growth prospect mapping
Fig. 12 Market driver relevance analysis (Current & future impact)
Fig. 13 Global population by age group, 2017, 2020, & 2028
Fig. 14 General trend shifts from laboratory to point-of-care
Fig. 15 Market restrain relevance analysis (Current & future impact)
Fig. 16 Porter’s five forces analysis
Fig. 17 SWOT analysis, by factor (Political & legal, economic and technological)
Fig. 18 Strategy mapping
Fig. 19 Competition categorization
Fig. 20 Company market share analysis - Molecular diagnostics market, 2020
Fig. 21 Company market share analysis - Molecular diagnostics, oncology, 2020
Fig. 22 Company market share analysis - Molecular diagnostics, pharmacogenomics, 2020
Fig. 23 Company market share analysis - Molecular diagnostics, infectious diseases, 2020
Fig. 24 Company market share analysis - Molecular diagnostics, genetic testing, 2020
Fig. 25 Company market share analysis - Molecular diagnostics, others (neurological disease, cardiovascular diseases, microbiology, others), 2020
Fig. 26 Company market share analysis - Molecular diagnostics, polymerase chain reaction, 2020
Fig. 27 Company market share analysis - Molecular diagnostics, in situ hybridization, 2020
Fig. 28 Company market share analysis - Molecular diagnostics, INAAT, 2020
Fig. 29 Company market share analysis - Molecular diagnostics, chips & microarrays, 2020
Fig. 30 Company market share analysis - Molecular diagnostics, mass spectrometry, 2020
Fig. 31 Company market share analysis - Molecular diagnostics, sequencing, 2020
Fig. 32 Company market share analysis - Molecular diagnostics, transcription mediated amplification, 2020
Fig. 33 North America Company market share analysis - Molecular diagnostics, oncology, 2020
Fig. 34 North America Company market share analysis - Molecular diagnostics, pharmacogenomics, 2020
Fig. 35 North America Company market share analysis - Molecular diagnostics, infectious diseases, 2020
Fig. 36 North America Company market share analysis - Molecular diagnostics, genetic testing, 2020
Fig. 37 North America Company market share analysis - Molecular diagnostics, others (neurological disease, cardiovascular diseases, microbiology, others), 2020
Fig. 38 North America Company market share analysis - Molecular diagnostics, polymerase chain reaction, 2020
Fig. 39 North America Company market share analysis - Molecular diagnostics, in situ hybridization, 2020
Fig. 40 North America Company market share analysis - Molecular diagnostics, INAAT, 2020
Fig. 41 North America Company market share analysis - Molecular diagnostics, chips & microarrays, 2020
Fig. 42 North America Company market share analysis - Molecular diagnostics, mass spectrometry, 2020
Fig. 43 North America Company market share analysis - Molecular diagnostics, sequencing, 2020
Fig. 44 North America Company market share analysis - Molecular diagnostics, transcription mediated amplification, 2020
Fig. 45 Europe Company market share analysis - Molecular diagnostics, oncology, 2020
Fig. 46 Europe Company market share analysis - Molecular diagnostics, pharmacogenomics, 2020
Fig. 47 Europe Company market share analysis - Molecular diagnostics, infectious diseases, 2020
Fig. 48 Europe Company market share analysis - Molecular diagnostics, genetic testing, 2020
Fig. 49 Europe Company market share analysis - Molecular diagnostics, others (neurological disease, cardiovascular diseases, microbiology, others), 2020
Fig. 50 Europe Company market share analysis - Molecular diagnostics, polymerase chain reaction, 2020
Fig. 51 Europe Company market share analysis - Molecular diagnostics, in situ hybridization, 2020
Fig. 52 Europe Company market share analysis - Molecular diagnostics, INAAT, 2020
Fig. 53 Europe Company market share analysis - Molecular diagnostics, chips & microarrays, 2020
Fig. 54 Europe Company market share analysis - Molecular diagnostics, mass spectrometry, 2020
Fig. 55 Europe Company market share analysis - Molecular diagnostics, sequencing, 2020
Fig. 56 Europe Company market share analysis - Molecular diagnostics, transcription mediated amplification, 2020
Fig. 57 Asia Pacific Company market share analysis - Molecular diagnostics, oncology, 2020
Fig. 58 Asia Pacific Company market share analysis - Molecular diagnostics, pharmacogenomics, 2020
Fig. 59 Asia Pacific Company market share analysis - Molecular diagnostics, infectious diseases, 2020
Fig. 60 Asia Pacific Company market share analysis - Molecular diagnostics, genetic testing, 2020
Fig. 61 Asia Pacific Company market share analysis - Molecular diagnostics, others (neurological disease, cardiovascular diseases, microbiology, others), 2020
Fig. 62 Asia Pacific Company market share analysis - Molecular diagnostics, polymerase chain reaction, 2020
Fig. 63 Asia Pacific Company market share analysis - Molecular diagnostics, in situ hybridization, 2020
Fig. 64 Asia Pacific Company market share analysis - Molecular diagnostics, INAAT, 2020
Fig. 65 Asia Pacific Company market share analysis - Molecular diagnostics, chips & microarrays, 2020
Fig. 66 Asia Pacific Company market share analysis - Molecular diagnostics, mass spectrometry, 2020
Fig. 67 Asia Pacific Company market share analysis - Molecular diagnostics, sequencing, 2020
Fig. 68 Asia Pacific Company market share analysis - Molecular diagnostics, transcription mediated amplification, 2020
Fig. 69 LATAM Company market share analysis - Molecular diagnostics, oncology, 2020
Fig. 70 LATAM Company market share analysis - Molecular diagnostics, pharmacogenomics, 2020
Fig. 71 LATAM Company market share analysis - Molecular diagnostics, infectious diseases, 2020
Fig. 72 LATAM Company market share analysis - Molecular diagnostics, genetic testing, 2020
Fig. 73 LATAM Company market share analysis - Molecular diagnostics, others (neurological disease, cardiovascular diseases, microbiology, others), 2020
Fig. 74 LATAM Company market share analysis - Molecular diagnostics, polymerase chain reaction, 2020
Fig. 75 C LATAM ompany market share analysis - Molecular diagnostics, in situ hybridization, 2020
Fig. 76 LATAM Company market share analysis - Molecular diagnostics, INAAT, 2020
Fig. 77 LATAM Company market share analysis - Molecular diagnostics, chips & microarrays, 2020
Fig. 78 LATAM Company market share analysis - Molecular diagnostics, mass spectrometry, 2020
Fig. 79 LATAM Company market share analysis - Molecular diagnostics, sequencing, 2020
Fig. 80 LATAM Company market share analysis - Molecular diagnostics, transcription mediated amplification, 2020
Fig. 81 MEA Company market share analysis - Molecular diagnostics, oncology, 2020
Fig. 82 MEA Company market share analysis - Molecular diagnostics, pharmacogenomics, 2020
Fig. 83 MEA Company market share analysis - Molecular diagnostics, infectious diseases, 2020
Fig. 84 MEA Company market share analysis - Molecular diagnostics, genetic testing, 2020
Fig. 85 MEA Company market share analysis - Molecular diagnostics, others (neurological disease, cardiovascular diseases, microbiology, others), 2020
Fig. 86 MEA Company market share analysis - Molecular diagnostics, polymerase chain reaction, 2020
Fig. 87 MEA Company market share analysis - Molecular diagnostics, in situ hybridization, 2020
Fig. 88 MEA Company market share analysis - Molecular diagnostics, INAAT, 2020
Fig. 89 MEA Company market share analysis - Molecular diagnostics, chips & microarrays, 2020
Fig. 90 MEA Company market share analysis - Molecular diagnostics, mass spectrometry, 2020
Fig. 91 MEA Company market share analysis - Molecular diagnostics, sequencing, 2020
Fig. 92 MEA Company market share analysis - Molecular diagnostics, transcription mediated amplification, 2020
Fig. 93 Company market position analysis
Fig. 94 Competitive dashboard analysis
Fig. 95 Regional network map
Fig. 96 Competitive Dashboard Analysis
Fig. 97 Molecular diagnostics market: Product outlook and key takeaways
Fig. 98 Molecular diagnostics market: Product movement analysis
Fig. 99 Instruments market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 100 Reagents market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 101 Others market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 102 Molecular diagnostics market: Test location outlook and key takeaways
Fig. 103 Molecular diagnostics market: Test location movement analysis
Fig. 104 PoC market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 105 Self-test or over the counter market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 106 Central laboratories market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 107 Molecular diagnostics market: Technology outlook and key takeaways
Fig. 108 Molecular diagnostics market: Technology movement analysis
Fig. 109 Polymerase chain reaction (PCR) market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 110 Nucleic acid extraction and purification market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 111 Others market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 112 Multiplex PCR market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 113 Other PCR market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 114 Instruments PCR market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 115 Reagents PCR market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 116 Others PCR market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 117 In situ hybridization (ISH) market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 118 Instruments ISH market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 119 Reagents ISH market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 120 Others ISH market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 121 INAAT market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 122 Instruments INAAT market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 123 Reagents INAAT market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 124 Others INAAT market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 125 Chips and microarrays market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 126 Instruments chips and microarrays market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 127 Reagents chips and microarrays market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 128 Others chips and microarrays market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 129 Mass spectrometry market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 130 Instruments mass spectrometry market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 131 Reagents mass spectrometry market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 132 Others mass spectrometry market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 133 Sequencing market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 134 Instruments sequencing market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 135 Reagents sequencing market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 136 Others sequencing market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 137 Transcription Mediated Amplification (TMA) market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 138 Instruments TMA market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 139 Reagents TMA market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 140 Others TMA market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 141 Others market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 142 Instruments others market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 143 Reagents others market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 144 Others market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 145 Molecular diagnostics market: Application outlook and key takeaways
Fig. 146 Molecular diagnostics market: Application movement analysis
Fig. 147 Oncology market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 148 Breast cancer market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 149 Prostate cancer market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 150 Colorectal cancer market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 151 Cervical cancer market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 152 Kidney cancer market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 153 Liver cancer market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 154 Blood cancer market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 155 Lung cancer market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 156 Other cancer market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 157 Pharmacogenomics market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 158 Infectious diseases market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 159 MRSA market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 160 Clostridium difficile market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 161 VRE market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 162 Carbapenem-resistant bacteria market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 163 Flu market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 164 RSV market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 165 Candida market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 166 TB and drug-resistant TB market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 167 Meningitis cancer market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 168 Gastrointestinal panel testing market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 169 Chlamydia market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 170 Gonorrhea market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 171 HIV market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 172 Hepatitis C market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 173 Hepatitis B market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 174 Other infectious disease market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 175 Genetic testing market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 176 Newborn screening market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 177 Predictive and presymptomatic testing market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 178 Other genetic testing market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 179 Neurological diseases market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 180 Cardiovascular diseases market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 181 Microbiology market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 182 Others market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 183 Molecular diagnostics market: Regional outlook and key takeaways
Fig. 184 Molecular diagnostics market: Regional movement analysis
Fig. 185 North America
Fig. 186 North America, SWOT
Fig. 187 North America market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 188 U.S.
Fig. 189 U.S. market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 190 Canada
Fig. 191 Canada market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 192 Europe
Fig. 193 Europe, SWOT
Fig. 194 Europe market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 195 U.K.
Fig. 196 U.K. market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 197 Germany
Fig. 198 Germany market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 199 France
Fig. 200 France market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 201 Spain
Fig. 202 Spain market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 203 Italy
Fig. 204 Italy market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 205 Belgium
Fig. 206 Belgium market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 207 Switzerland
Fig. 208 Switzerland market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 209 Netherlands
Fig. 210 Netherlands market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 211 Poland
Fig. 212 Poland market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 213 Austria
Fig. 214 Austria market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 215 Greece
Fig. 216 Greece market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 217 Sweden
Fig. 218 Sweden market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 219 Turkey
Fig. 220 Turkey market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 221 Finland
Fig. 222 Finland market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 223 Asia Pacific
Fig. 224 Asia Pacific, SWOT
Fig. 225 Asia Pacific market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 226 Japan
Fig. 227 Japan market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 228 China
Fig. 229 China. market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 230 India
Fig. 231 India market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 232 Australia
Fig. 233 Australia market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 234 New Zealand
Fig. 235 New Zealand market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 236 Sri Lanka
Fig. 237 Sri Lanka market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 238 Malaysia
Fig. 239 Malaysia market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 240 Thailand
Fig. 241 Thailand market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 242 Vietnam
Fig. 243 Vietnam market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 244 Singapore
Fig. 245 Singapore market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 246 Latin America
Fig. 247 Latin America, SWOT
Fig. 248 Latin America. market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 249 Brazil
Fig. 250 Brazil market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 251 Mexico
Fig. 252 Mexico market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 253 Colombia
Fig. 254 Colombia market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 255 Chile
Fig. 256 Chile market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 257 Peru
Fig. 258 Peru market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 259 Argentina
Fig. 260 Argentina market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 261 Middle East & Africa
Fig. 262 Middle East & Africa, SWOT
Fig. 263 Middle East & Africa market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 264 South Africa
Fig. 265 South Africa market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 266 Saudi Arabia
Fig. 267 Saudi Arabia market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 268 Jordan
Fig. 269 Jordan market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 270 United Arab Emirates
Fig. 271 United Arab Emirates market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 272 Qatar
Fig. 273 Qatar market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 274 Nigeria
Fig. 275 Nigeria market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 276 Egypt
Fig. 277 Egypt market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 278 Strategy Framework
Fig. 279 Participant categorization
Note: Product cover images may vary from those shown
  • Abbott
  • Becton, Dickinson and Company
  • bioMérieux SA
  • Bio-Rad Laboratories, Inc.
  • Agilent Technologies, Inc.
  • Danaher Corporation
  • Hologic, Inc. (Gen Probe)
  • Illumina, Inc.
  • Johnson & Johnson Services, Inc.
  • GRIFOLs S.A.
  • Qiagen
  • F. Hoffmann-La Roche Ltd
  • Siemens Healtineers
  • Sysmex Corporation
Note: Product cover images may vary from those shown

Loading
LOADING...

Adroll
adroll